Skip to main content Accessibility help

We use cookies to distinguish you from other users and to provide you with a better experience on our websites. Close this message to accept cookies or find out how to manage your cookie settings.

Close cookie message
×
Hostname: page-component-6bf8c574d5-2jptb Total loading time: 0 Render date: 2025-02-23T12:42:11.907Z Has data issue: false hasContentIssue false

Tolterodine

Published online by Cambridge University Press:  20 February 2025

K. Ray Chaudhuri ,
Peter Jenner ,
Valentina Leta ,
Shelley Jones  and
Iro Boura
K. Ray Chaudhuri
Affiliation:
King's College London
Peter Jenner
Affiliation:
King's College London
Valentina Leta
Affiliation:
King's College London
Shelley Jones
Affiliation:
King's College London
Iro Boura
Affiliation:
St. George General Hospital of Chania, Crete, Greece
Get access

Summary

Tolterodine tartrate ((+)-(R)-2-{α-[2-(di-isopropylamino)ethyl]benzyl}-p-cresol tartrate) is the tartrate salt form of tolterodine. It has a molecular weight of 475.6 and a molecular formula of C22H31NO,C4H6O6. One milligram of tolterodine tartrate corresponds to 0.68 mg of tolterodine.

Type
Chapter
Information
The Movement Disorders Prescriber's Guide to Parkinson's Disease , pp. 494 - 504
Publisher: Cambridge University Press
Print publication year: 2025

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

Suggested Reading

Abrams, P, Freeman, R, Anderström, C, Mattiasson, A. Tolterodine, a new antimuscarinic agent: as effective but better tolerated than oxybutynin in patients with an overactive bladder. Br J Urol 1998; 81(6): 801–810.CrossRefGoogle ScholarPubMed
Appell, RA. Clinical efficacy and safety of tolterodine in the treatment of overactive bladder: a pooled analysis. Urology 1997; 50(6A Suppl): 90–96; discussion 97–99.CrossRefGoogle ScholarPubMed
Rovner, ES. Tolterodine for the treatment of overactive bladder: a review. Expert Opin Pharmacother 2005; 6(4): 653–666.CrossRefGoogle ScholarPubMed
Van Kerrebroeck, P, Kreder, K, Jonas, U, Zinner, N, Wein, A. Tolterodine once-daily: superior efficacy and tolerability in the treatment of the overactive bladder. Urology 2001; 57(3): 414–421.CrossRefGoogle ScholarPubMed

References

AHFS Drug information, 2012. Bethesda: American Society of Health-System Pharmacists. Accessed on 29 December 2022 via www.medicinescomplete.com.Google Scholar
Appell, RA, Abrams, P, Drutz, HP, Van Kerrebroeck, PE, Millard, R, Wein, A. Treatment of overactive bladder: long-term tolerability and efficacy of tolterodine. World J Urol 2001; 19(2): 141–147.CrossRefGoogle ScholarPubMed
Chung, DE, Te, AE. Tolterodine extended-release for overactive bladder. Expert Opin Pharmacother 2009; 10(13): 2181–2194.CrossRefGoogle ScholarPubMed
Duong, V, Iwamoto, A, Pennycuff, J, Kudish, B, Iglesia, C. A systematic review of neurocognitive dysfunction with overactive bladder medications. Int Urogynecol J 2021; 32(10): 2693–2702.CrossRefGoogle ScholarPubMed
Joint Formulary Committee. British National Formulary (online). London: BMJ Group and Pharmaceutical Press. Accessed on 29 December 2022 via www.medicinescomplete.com.Google Scholar
Madhuvrata, P, Cody, JD, Ellis, G, Herbison, GP, Hay-Smith, EJ. Which anticholinergic drug for overactive bladder symptoms in adults. Cochrane Database Syst Rev 2012; 1: CD005429.Google ScholarPubMed
Malone-Lee, JG, Walsh, JB, Maugourd, MF. Tolterodine: a safe and effective treatment for older patients with overactive bladder. J Am Geriatr Soc 2001; 49(6): 700–705.CrossRefGoogle ScholarPubMed
Stahl, MM, Ekström, B, Sparf, B, Mattiasson, A, Andersson, KE. Urodynamic and other effects of tolterodine: a novel antimuscarinic drug for the treatment of detrusor overactivity. Neurourol Urodyn 1995; 14(6): 647–655.CrossRefGoogle ScholarPubMed
Summary of product characteristics – Detrusitol 2 mg film-coated tablets. Upjohn UK Ltd. Electronic Medicines Compendium: Detrusitol 2 mg film-coated tablets – summary of product characteristics (SmPC) – (emc). Accessed on 24 February 2023 via www.medicines.org.uk.Google Scholar
Takei, M, Homma, Y. Long-term safety, tolerability and efficacy of extended-release tolterodine in the treatment of overactive bladder in Japanese patients. Int J Urol 2005; 12(5): 456–464.CrossRefGoogle ScholarPubMed
Tolterodine. In: Brayfield, A (Ed.), Martindale: The Complete Drug Reference. London: The Royal Pharmaceutical Society of Great Britain. Accessed on 1 January 2023 via www.medicinescomplete.com.Google Scholar
Tolterodine. In: DRUGDEX® System (electronic version). Truven Health Analytics, Greenwood Village, Colorado, USA. Accessed on 29 December 2022 via www.micromedexsolutions.com.Google Scholar
Wang, HT, Xia, M. Comparisons of therapeutic efficacy and safety of solifenacin versus tolterodine in patients with overactive bladder: a meta-analysis. Urol Int 2019; 103(2): 187–194.CrossRefGoogle ScholarPubMed
Yang, N, Wu, Q, Xu, F, Zhang, X. Comparisons of the therapeutic safety of seven oral antimuscarinic drugs in patients with overactive bladder: a network meta-analysis. J Int Med Res 2021; 49(9): 3000605211042994.CrossRefGoogle ScholarPubMed
Zinner, NR, Mattiasson, A, Stanton, SL. Efficacy, safety, and tolerability of extended-release once-daily tolterodine treatment for overactive bladder in older versus younger patients. J Am Geriatr Soc 2002; 50(5): 799–807.CrossRefGoogle ScholarPubMed

Save book to Kindle

To save this book to your Kindle, first ensure [email protected] is added to your Approved Personal Document E-mail List under your Personal Document Settings on the Manage Your Content and Devices page of your Amazon account. Then enter the ‘name’ part of your Kindle email address below. Find out more about saving to your Kindle.

Note you can select to save to either the @free.kindle.com or @kindle.com variations. ‘@free.kindle.com’ emails are free but can only be saved to your device when it is connected to wi-fi. ‘@kindle.com’ emails can be delivered even when you are not connected to wi-fi, but note that service fees apply.

Find out more about the Kindle Personal Document Service.

  • Tolterodine
  • K. Ray Chaudhuri, King's College London, Peter Jenner, King's College London, Valentina Leta, King's College London, Shelley Jones, King's College London, Iro Boura, St. George General Hospital of Chania, Crete, Greece
  • Book: The Movement Disorders Prescriber's Guide to Parkinson's Disease
  • Online publication: 20 February 2025
  • Chapter DOI: https://doi.org/10.1017/9781009222648.050
Available formats
×

Save book to Dropbox

To save content items to your account, please confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your account. Find out more about saving content to Dropbox.

  • Tolterodine
  • K. Ray Chaudhuri, King's College London, Peter Jenner, King's College London, Valentina Leta, King's College London, Shelley Jones, King's College London, Iro Boura, St. George General Hospital of Chania, Crete, Greece
  • Book: The Movement Disorders Prescriber's Guide to Parkinson's Disease
  • Online publication: 20 February 2025
  • Chapter DOI: https://doi.org/10.1017/9781009222648.050
Available formats
×

Save book to Google Drive

To save content items to your account, please confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your account. Find out more about saving content to Google Drive.

  • Tolterodine
  • K. Ray Chaudhuri, King's College London, Peter Jenner, King's College London, Valentina Leta, King's College London, Shelley Jones, King's College London, Iro Boura, St. George General Hospital of Chania, Crete, Greece
  • Book: The Movement Disorders Prescriber's Guide to Parkinson's Disease
  • Online publication: 20 February 2025
  • Chapter DOI: https://doi.org/10.1017/9781009222648.050
Available formats
×